

Factsheet FY/2012



COMPANY PROFILE

Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. Approximately 170,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	2012	2011	2010	2009
Sales and Earnings				
Sales ¹	19,290	16,361	15,972	14,164
EBIT ²	3,075	2,563	2,418	2,054
Net income (before special items) ³	938	770	660	514
Earnings per ord. share in € (before special items) ³	5.42	4.73	4.08	3.18
Balance sheet and cash flow				
Total assets	30,664	26,321	23,577	20,882
Non-current assets	22,551	19,170	17,142	15,519
Equity ⁴	12,758	10,577	8,844	7,491
Equity ratio ⁴	42%	40%	38%	36%
Net debt/EBITDA ⁵	2.6	2.8	2.6	3.0
Investments ⁶	4,179	2,395	1,402	931
Operating cash flow	2,438	1,689	1,911	1,553
Operating cash flow in % of sales	12.6%	10.3%	12.0%	11.0%
Profitability				
EBIT margin ²	15.9%	15.7%	15.1%	14.5%
Return on equity after taxes (ROE) ³	12.3%	12.9%	13.3%	12.1%
Return on operating assets (ROOA) ²	11.0%	10.9%	11.6%	10.5%
Return on invested capital (ROIC) ²	9.0%	8.8%	8.9%	8.2%
Employees (December 31)	169,324	149,351	137,552	130,510

¹ 2011 sales were adjusted by -€161 million according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America.

² 2012 adjusted for one-time costs (€6 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG as well as for other one-time costs (€86 million) at Fresenius Medical Care.

³ Net income attributable to shareholders of Fresenius SE & Co. KGaA, 2012 adjusted for a non-taxable investment gain (€34 million) and other one-time costs (€17 million) at Fresenius Medical Care as well as for one-time costs (€29 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG. 2009–2011 adjusted for the effects of mark-to-market accounting of the MEB and the CVR.


⁴ Including noncontrolling interest

⁵ 2012 before special items

⁶ Investments in property, plant and equipment and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of December 31, 2012


BUSINESS SEGMENTS

€ in millions	2012		2011	
	Sales	EBIT	Sales	EBIT
FRESENIUS MEDICAL CARE	10,741	1,813	9,031 ¹	1,491
FRESENIUS KABI	4,539	934	3,964	803
FRESENIUS HELIOS	3,200	322	2,665	270
FRESENIUS VAMED	846	51	737	44


¹ 2011 sales were adjusted by -€161 million according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America.

- ▶ **Fresenius Medical Care** is the world's leading provider of services and products for patients with chronic kidney failure. As of December 31, 2012, Fresenius Medical Care was treating 257,916 patients in 3,160 dialysis clinics.
- ▶ **Fresenius Kabi** offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products in Germany.
- ▶ **Fresenius Helios** is one of the largest private hospital operators in Germany. HELIOS owns 72 hospitals, including 6 maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin and Wuppertal. HELIOS treats more than 2.9 million patients per year, thereof more than 770,000 inpatients, and operates more than 23,000 beds.
- ▶ **Fresenius Vamed** offers engineering and services for hospitals and other health care facilities.

SALES BY REGION



SALES BY BUSINESS SEGMENT



FRESENIUS SHARE/ADR


	Ordinary share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of ordinary shares (December 31, 2012)	178,188,260
Market capitalization (December 31, 2012)	€15.5 billion

FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Maturity
Fresenius Finance B. V.	XS0759200321	€500	4.25%	2019
Fresenius Finance B. V.	XS0873432511	€500	2.875%	2020
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00%	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75%	2015

Bonds of Fresenius Medical Care can be found under [www.fmc-ag.com/Credit Relations](http://www.fmc-ag.com/Credit_Relations).

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX




SHARE PERFORMANCE¹

1 month	-2.0%
4 th quarter	-5.6%
1 year	+21.6%
5 years	+55.5%
10 years	+624.8%

¹ Effective date/closing price: December 31, 2012

DEVELOPMENT ORDINARY SHARE DIVIDENDS IN €



¹ Proposal

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Mats Henriksson, Dr. Francesco De Meco, Dr. Jürgen Götz, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

GROUP OUTLOOK 2013

	Targets 2013
Sales growth ¹ (in constant currency)	7% – 10%
Net income ² , growth (in constant currency)	7% – 12%
Capital expenditure	~5% of group sales

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 adjusted for one-time integration costs of Fenwal, Inc. (~€50 million pre tax); 2012 adjusted for an investment gain and other one-time costs at Fresenius Medical Care as well as for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG.

For the outlook of the business segments please see the Investor News of February 26, 2013.

FINANCIAL CALENDAR

	Dates
Report on 1 st quarter 2013	April 30, 2013
Annual General Meeting, Frankfurt/Main	May 17, 2013
Payment of dividend ¹	May 20, 2013
Report on 1 st half 2013	July 30, 2013
Report on 1 st –3 rd quarter 2013	November 5, 2013

¹ Subject to prior approval by the Annual General Meeting

CONTACT

Fresenius SE & Co. KGaA

Birgit Grund
Senior Vice President
Investor Relations
Else-Kröner-Straße 1
61352 Bad Homburg v. d. H.

Telephone: ++49 61 72 6 08-24 85
Telefax: ++49 61 72 6 08-24 88
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.de